Nutrachampion podcast episode 19

Listen – ‘Evidence-based priority’: Dr Janet Schloss’ cancer nutrition mission to combat misleading claims

This content item was originally published on, a William Reed online publication.

By Tingmin Koe contact

- Last updated on GMT

Listen – ‘Evidence-based priority’: Dr Janet Schloss’ cancer nutrition mission to combat misleading claims

Related tags: Cbd, Cancer, Cannabis

Consumers suffering from chronic diseases or cancer could be vulnerable to the empty promises and misleading health claims, which is why Dr Janet Schloss, the latest guest on our NutraChampion podcast, has made it her mission to drive an evidence-based approach to nutrition.

Currently a clinical research fellow at the National Centre for Naturopathic Medicine at Australia’s Southern Cross University, Dr Janet Schloss’ areas of expertise include herbal medicines and oncology, nutrition and dietetics, and nutritional biochemistry.

Some of the nutritional interventions that she has explored for cancer patients include vitamin B12 for reducing the onset and severity of chemotherapy-induced peripheral neuropathy as well as medicinal cannabis.

Dr Janet Schloss
Dr Janet Schloss

In May, she and her colleagues published new findings on how the use of cannabidiol (CBD) and tetrahydrocannabinol (THC) is safe in patients suffering from advanced stage brain cancer.

The combination has also shown to improve the patients’ quality of life, sleep, and functional wellbeing.

Dr Schloss, who has published nearly 80 scientific papers, revealed that it was her auntie’s experience with bowel cancer and consumption of supplements with fake promises that impacted her decision to study cancer and nutrition.

“When I was initially studying, my auntie had bowel cancer and chose not to do medical treatment, and there was this person who was not qualified but gave different supplements to my auntie and she actually had a terrible death.

“And part of me decided that this is an area that I want to specialise in, and I want to make sure that we do evidence-based [research], so that nobody has to go through what my auntie went through,”​ she said.  

Her upcoming research will look at medicinal cannabis’ benefits in brain cancer patients when compared to the placebo. The previous study only compared the effects of THC to CBD at the ratios of 4:1 and 1:1 without a placebo group.  

She is also interested to find out the delivery system that could allow medicinal cannabis to be delivered into the patients without having to cross the blood-brain barrier.

Listen to find out more.

Related news

Related products

show more

Reach Consumers with Fruit & Vegetable Powders

Reach Consumers with Fruit & Vegetable Powders

vaneeghen | 08-Sep-2021 | Technical / White Paper

Are you looking to create products that appeal to today’s plant-forward consumers? The plant-based revolution continues to captivate the market as consumers...

Turmacin®: Clean Label & Clinically Tested Turmeric

Turmacin®: Clean Label & Clinically Tested Turmeric

Natural Remedies Private Limited | 01-Sep-2021 | Product Presentation

Turmacin® is a clean label project-certified, clinically tested, and clinically safe turmeric extract. Turmacin® is rich in Turmerosaccharides® and doesn't...

How to Enter UK’s £690M CBD Market

How to Enter UK’s £690M CBD Market

The Association for the Cannabinoid Industry | 18-Jun-2021 | Technical / White Paper

The UK has the world’s most developed regulatory framework for legal cannabinoids, such as CBD and CBG. With a 2021 market estimated to be worth £690 million...

Your bioavailable and soluble anti-aging curcumin

Your bioavailable and soluble anti-aging curcumin

Lipofoods, a Lubrizol Company | 11-Jun-2021 | Technical / White Paper

Curcumin´s antioxidant and anti-inflammatory potential is limited by its poor solubility and its low bioavailability. In this respect, Lubrizol microencapsulated...

Related suppliers

Follow us


View more